Axoft, a neurotechnology firm based in Cambridge, Massachusetts, has successfully secured $55 million in a Series A funding round led by C.P. Group Innovation, with participation from notable investors including Alumni Ventures, the Stanford President’s Venture Fund, Hillhouse Investment, and Gaorong Ventures. This brings the company's total funding to over $60 million.
The newly acquired funds will primarily support Axoft in expanding its clinical trials globally and advancing the regulatory approval process for its implantable Brain-Computer Interfaces (iBCIs) in the U.S. These iBCIs have shown promising results in safely decoding brain signals, a critical step toward developing effective treatments for neurological disorders.
Dr. Paul Le Floch, co-founder and CEO, emphasized that the quality of neural data captured by Axoft's iBCIs not only enhances their efficacy but also facilitates minimally invasive surgeries and access to deeper brain regions. The funding will also enable the establishment of a good manufacturing practice (GMP) facility to mass-produce these innovative devices.
Axoft's proprietary material, Fleuron, is a significant advancement in this space, offering superior biocompatibility and enhanced neural data capture capabilities compared to traditional materials. This positions the company favorably in both clinical applications and broader biomedical engineering contexts, potentially paving the way for new treatments and technologies.